Researchers have used comparative metabologenomics to uncover what may be “silencing” bacteria to produce desirable compounds.
List view / Grid view
Acetate was found to be involved in regulating complex microbes and could help trigger an immune response against harmful bacteria in mice.
Researchers have screened bacteria in the gut, finding that Bifidobacteria have inhibitory activity against SARS-CoV-2.
Researchers have developed a native state mass spectrometry technique to identify inhibitors of the bacterial protein metallo-beta-lactamase.
Exosomes containing salmonella antigens were administered to the mice, enabling the models to develop antibodies against the bacteria.
A new artificial intelligence (AI) method has been created to uncover which proteins enable bacteria to infect human intestines.
Researchers have developed a platform named FAST to produce antibiotics that specifically target just the bacteria of interest.
A team has created a biosynthetic pathway for E. coli that allows the bacteria to produce a common arthritis drug.
This article introduces insights into combatting multidrug resistance via high-throughput laboratory evolution, pointing to the mechanisms of underlying evolved drug resistance.
Using single-cell RNA sequencing, researchers have shown that interferon response is correlated with tuberculosis progression.
A study has shown that the ES17 phage binds to heparan sulphate and can target and eliminate ExPEC bacteria in animal models.
Researchers have shown that CBD can kill Gram-negative bacteria, which could lead to the first new class of antibiotics for resistant bacteria in 60 years.
Scientists have identified a potential alternative to antibiotics, a nutrient named taurine that helps the microbiome kill invading bacteria.
The role that retrons in bacteria has been discovered by researchers, who found they protect colonies when infected by viruses.
The National Institute of Health envisions a plan for managing tuberculosis in the 21st century. Included in this proposal is targeting host proteins as an add-on therapy to antibiotics. Infectious disease biologists are focusing on this strategy and it is a topic of active research. Recently, a multinational research team…